Home > Companies > Touchlight Genetics Ltd

Touchlight Genetics Ltd

touchlight.com

Touchlight is a biotechnology company focused on the development, commercialization and licensing of doggybone or dbDNA™ based therapeutics and technologies. Touchlight’s doggybone DNA is a novel, linear, synthetic DNA vector with a unique expression profile, produced using a revolutionary enzymatic technology. Touchlight’s ambition is to advance genetic medicines to improve the treatment of disease and to underpin the future of DNA with our technology.

C-Suite On Deck

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Events

8th International Conference on Bio-Sensing Technology

Conference

Related News

LIFEMINE THERAPEUTICS AND GSK ENTER DRUG DISCOVERY AND DEVELOPMENT ALLIANCE

LifeMine | March 28, 2022

LifeMine Therapeutics Inc., a biopharmaceutical company reinventing drug discovery by mining genetically-encoded small molecules (GEMs) from the biosphere, today announced a strategic R&D collaboration with GlaxoSmithKline (GSK). The collaboration will provide GSK with access to LifeMine’s genomically enabled drug discovery platform to identify novel small molecule leads directed to up to three human targets provided by GSK addressing multiple disease areas. Under the te...

MedTech

BIOCYTOGEN LISTS ON THE MAIN BOARD OF HKEX, AIMING TO BECOME THE HEADSTREAM OF NEW DRUGS

Biocytogen | September 02, 2022

Biocytogen Pharmaceuticals Co., Ltd. nnounced the company’s official listing on the Main Board of the Stock Exchange of Hong Kong. Government representatives, shareholders, agencies, collaborative partners, and employee representatives attended the listing ceremony. In total, 21.76 million shares were offered globally with a price of HK$ 25.22 per share. The net proceeds from the Global Offering will be approximately HK$ 471.1 million. Since its establishment in 2009, Biocyt...

Medical

ANITOA LAUNCHES MOLECULAR TEST (PCR) FOR MONKEYPOX

Anitoa | June 30, 2022

Anitoa Systems, market leader in fast, portable molecular testing, today announced the availability of a CE-marked turn-key PCR solution for testing Monkeypox. This portable solution includes one of a family small foot-print real time PCR instruments called the Maverick qPCR, with an extraction-free multiplex PCR reagent that tests OPXV/MPXV gene-targets in the skin lesion sample from patients suspected of infection with Monkeypox. Anitoa's Monkeypox test is designed to be carried out on-sit...

Medical

HERON THERAPEUTICS ANNOUNCES FDA APPROVAL OF ZYNRELEF® INDICATION EXPANSION TO INCLUDE ADDITIONAL ORTHOPEDIC AND SOFT TISSUE PROCEDURES

Heron Therapeutics, Inc. | January 29, 2024

Heron Therapeutics, Inc. a commercial-stage biotechnology company announced that the U.S. Food and Drug Administration (the "FDA") has approved its supplemental New Drug Application ("NDA") for ZYNRELEF® extended-release solution to expand the indication for soft tissue and orthopedic surgical procedures including foot and ankle, and other procedures in which direct exposure to articular cartilage is avoided. ZYNRELEF was previously approved for foot and ankle, smal...